Gastrointestinal Cancers

Expert faculty review and share their insights and perspectives on key findings in gastrointestinal cancers presented at the 2020 ASCO Annual Meeting

Share

Program Content

Activities

  • Expert Analysis
    Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 07, 2020

    Expires: August 06, 2021

  • Downloadable Slideset
    Key Studies in Gastrointestinal Cancers from the 2020 ASCO Virtual Scientific Meeting
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 07, 2020

    Expires: August 06, 2021

Activities

DESTINY-CRC01
Phase II DESTINY-CRC01: Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

PRODIGE 23
PRODIGE 23: Phase III Trial of Neoadjuvant mFOLFIRINOX Plus CRT vs Preoperative CRT in Locally Advanced Rectal Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2020

Expires: June 04, 2021

RTOG 1010
Phase III RTOG 1010: Addition of Trastuzumab to Trimodality Treatment in Resectable HER2-Positive Esophageal Adenocarcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2020

Expires: June 01, 2021

SWOG S1505
SWOG S1505: Phase II Study of Perioperative CT With mFOLFIRINOX vs Gemcitabine/nab-Paclitaxel in Resectable Pancreatic Ductal Adenocarcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2020

Expires: June 03, 2021

DESTINY-Gastric01
DESTINY-Gastric01: Trastuzumab Deruxtecan in Previously Treated, HER2+ Advanced Gastric or GEJ Adenocarcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

KEYNOTE-177
KEYNOTE-177: Phase III Trial of First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2020

Expires: June 03, 2021

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.